Related Experiment Video
Updated: Dec 15, 2025
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
Giandomenico Roviello1, Andrea Casadei-Gardini2, Stefania Nobili1
1Department of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy.
Background:
Second line of treatment of hepatocellular carcinoma (HCC) has notably changed in recent years as three novel drugs with a different mechanism of action have demonstrated to improve survival compared to placebo; thus, there is a need to better define the profile of optimal candidates to second-line treatment with these drugs in order to maximize clinical benefit.
Materials And Methods:
We performed a pooled analysis from the subgroup analysis of all published phase III trials for approved targeted therapy in the second line of treatment for HCC, with the aim to discover possible clinical-pathological predictive factors.
Results:
Four studies were included in the analysis for a total of 2137 cases whose results supported the use of these novel agents in male patients with ECOG: 0, extrahepatic metastases, and HBV infection.
Conclusions:
Future studies are awaited to define best candidates for novel agents approved in the second line of treatment for HCC.
Insights
Novel targeted therapies improve survival in second-line hepatocellular carcinoma (HCC) treatment. This study identified male patients with ECOG 0, extrahepatic metastases, and HBV infection as optimal candidates for these agents.
Area of Science:
- Hepatobiliary Oncology
- Medical Oncology
- Translational Research
Background:
- Second-line treatment for hepatocellular carcinoma (HCC) has evolved with new targeted therapies.
- These novel drugs offer improved survival compared to placebo.
- Optimizing patient selection for these agents is crucial for maximizing clinical benefit.
Purpose of the Study:
- To identify clinical-pathological predictive factors for optimal patient selection in second-line HCC treatment.
- To evaluate the efficacy of novel targeted therapies in specific HCC patient subgroups.
Main Methods:
- Pooled analysis of subgroup data from published phase III trials.
- Included trials focused on approved targeted therapies for second-line HCC treatment.
Main Results:
- Analysis of four studies involving 2137 HCC cases.
- Results suggest favorable outcomes for male patients with ECOG performance status 0, extrahepatic metastases, and HBV infection.
Conclusions:
- Further research is needed to precisely define the optimal candidates for novel second-line HCC therapies.
- Identifying predictive biomarkers will enhance treatment efficacy and patient outcomes.
More Related Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019